Royalty Pharma (RPRX) to Release Earnings on Thursday

Royalty Pharma (NASDAQ:RPRX) is expected to be releasing its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of $1.02 per share and revenue of $724.69 million for the quarter.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, analysts expect Royalty Pharma to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Royalty Pharma Stock Up 0.3 %

Shares of NASDAQ RPRX opened at $32.82 on Thursday. The firm’s 50-day moving average is $32.50 and its two-hundred day moving average is $29.53. The company has a market capitalization of $18.92 billion, a PE ratio of 22.63, a price-to-earnings-growth ratio of 2.31 and a beta of 0.50. Royalty Pharma has a 12-month low of $24.05 and a 12-month high of $34.20. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a dividend of $0.22 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 annualized dividend and a dividend yield of 2.68%. Royalty Pharma’s dividend payout ratio is currently 60.69%.

Wall Street Analysts Forecast Growth

Separately, Citigroup reissued a “buy” rating on shares of Royalty Pharma in a research report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Royalty Pharma has a consensus rating of “Buy” and an average price target of $42.50.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.